Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NeuroVive Pharmaceutical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NeuroVive Pharmaceutical's earnings available for a low price, and how does
this compare to other companies in the same industry?
NeuroVive Pharmaceutical is not considered high growth as it is expected to be loss making for the next 1-3 years.
NeuroVive Pharmaceutical's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NeuroVive Pharmaceutical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
NeuroVive Pharmaceutical's finances.
The net worth of a company is the difference between its assets and liabilities.
NeuroVive Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
NeuroVive Pharmaceutical has no long term commitments.
This treemap shows a more detailed breakdown of
NeuroVive Pharmaceutical's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
NeuroVive Pharmaceutical has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Erik Kinnmann, M.D., Ph.D., M.B.A., Assoc. Prof. has been the Chief Executive Officer of NeuroVive Pharmaceutical AB since March 14, 2016. Mr. Kinnmann served as the Chief Medical Officer of Infant Bacterial Therapeutics AB. He served as Vice President of Investor Relations, Director of Business Strategy and Medical Advisor of Neurology at PledPharma AB. He served as the Chief Strategic Officer and Vice President of Investor Relations & Public Affairs of Swedish Orphan Biovitrum AB since March 2008 and served as its Head of Investor Relations & Public Affairs and Executive Vice President. He has 19 years experience in the pharmaceutical industry, including relevant knowledge and experience on orphan drug development (AstraZeneca, SOBI, Wilson Therapeutics, Biocrine, Sanofi, Pfizer). He has an extensive experience from the financial sector. He has an impressive knowledge and combined pharmaceutical industry and health care financial sector experience. Mr. Kinnmann held a number of senior leadership positions within AstraZeneca, Sanofi-Synthelabo Scandinavia and Parke-Davies/Warner-Lambert Norden AB. He served as the Head of a health care sector analysis team of Danske Securities AB. Prior to that, he served as a Health Care Fund Manager of Aragon Fondkommission AB. He served as an Associate Professor in experimental and clinical pain research at Karolinska Institutet. Mr. Kinnmann holds an MBA from the Stockholm School of Economics and Ph.D. from the Karolinska Institutet. He is a MD, Board Certified in Neurology and Pain Management.
Erik's compensation has increased whilst company is loss making.
Erik's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the NeuroVive Pharmaceutical management team is about average.
Chief Executive Officer
CFO & VP of Investor Relations
Chief Scientific Officer & VP of Discovery
Director of Communications
Chief Medical Officer and VP of Preclinical & Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the NeuroVive Pharmaceutical board of directors is less than 3 years, this suggests a new board.
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.